GlaxoSmithKline PLC (LON:GSK) Rating
In a research note sent to investors on today, Jefferies International reaffirmed their “Hold” rating on GlaxoSmithKline PLC (LON:GSK)’s stock. The target price per share would indicate a potential downside of -8.08% from firm’s current stock price.
Out of 23 analysts covering GlaxoSmithKline PLC (LON:GSK), 5 rate it “Buy”, 2 “Sell”, while 16 “Hold”. This means 22% are positive. GBX 1800 is the highest target while GBX 1250 is the lowest. The GBX 1469.90 average target is 8.09% above today’s (GBX 1359.84) stock price. GlaxoSmithKline PLC was the topic in 86 analyst reports since July 28, 2015 according to StockzIntelligence Inc. JP Morgan maintained the stock on November 17 with “Neutral” rating. Societe Generale maintained it with “Sell” rating and GBX 1250 target price in a November 4 report. J.P. Morgan maintained the shares of GSK in a report on November 11 with “Neutral” rating. Liberum Capital maintained the firm’s rating on November 4. Liberum Capital has “Hold” rating and GBX 1350 price target. Finally, Barclays Capital maintained the stock with “Overweight” rating in a November 5 report.
The stock increased 3.49% or GBX 45.84 on November 17, hitting GBX 1359.84. About 6.94 million shares traded hands. GlaxoSmithKline plc (LON:GSK) has declined 14.57% since April 21, 2015 and is downtrending. It has underperformed by 12.03% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 66.11 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.69 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
GlaxoSmithKline PLC - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.